Evidence map›Paper›PMID 20623096›Full record

ReviewTheScientificWorldJournal2010

New concepts in phospholipase D signaling in inflammation and cancer.

Julian Gomez-Cambronero

Open access · goldAbstract readReview
In one paragraph

Review in TheScientificWorldJournal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Insights from DOCK2 in cell function and pathophysiology.Frontiers in molecular biosciences · 2022
    Review
  8. Article
  9. Identification and functional analysis of a novel phospholipase D2 gene mutation associated with familial systemic lupus erythematosus.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021
    Article
  10. D-series Resolvins activate Phospholipase D in phagocytes during inflammation and resolution.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Julian Gomez-CambroneroDepartment of Biochemistry and Molecular Biology, Wright State University School Medicine, Dayton, OH, USA. julian.cambronero@wright.edu
Wright State University · US

Funding

PLD2, as a GEF or as a Lipase, is Central to Leukocyte ChemotaxisR01HL056653 · NHLBI · WRIGHT STATE UNIVERSITY · PI CAMBRONERO, JULIAN G. · 2004 to 2016
$4.0M
SIGNAL TRANSDUCTION IN NEUTROPHIL MEDIATED HEART INJURYR29HL056653 · NHLBI · WRIGHT STATE UNIVERSITY · PI GOMEZ-CAMBRONERO, JULIAN · 1998 to 2002
$301k
NHLBI NIH HHS HL056653NHLBI NIH HHS R01 HL056653NHLBI NIH HHS R29 HL056653
6 · The paper itself

Abstract

Phospholipase D (PLD) catalyzes the hydrolysis of phosphatidylcholine to generate the lipid second messenger phosphatidic acid (PA) and choline. PLD regulation in cells falls into two major signaling categories. One is via growth factors/mitogens, such as EGF, PDGF, insulin, and serum, and implicates tyrosine kinases; the other is via the small GTPase proteins Arf and Rho. We summarize here our lab's and other groups' contributions to those pathways and introduce several novel concepts. For the mitogen-induced signaling, new data indicate that an increase in cell transformation in PLD2-overexpressing cells is due to an increase of de novo DNA synthesis induced by PLD2, with the specific tyrosine residues involved in those functions being Y179 and Y511. Recent research has also implicated Grb2 in tyrosine phosphorylation of PLD2 that also involves Sos and the ERK pathway. The targets of phosphorylation within the PLD2 molecule that are key to its regulation have recently been precisely mapped. They are Y296, Y415, and Y511 and the responsible kinases are, respectively, EGFR, JAK3, and Src. Y296 is an inhibitory site and its phosphorylation explains the low PLD2 activity that exists in low-invasive MCF-7 breast cancer cells. Advances along the small GTPase front have implicated cell migration, as PLD1 and PLD2 cause an increase in chemotaxis of leukocytes and inflammation. PA is necessary for full chemotaxis. PA enriches the localization of the atypical guanine exchange factor (GEF), DOCK2, at the leading edge of polarized neutrophils. Further, extracellular PA serves as a neutrophil chemoattractant; PA enters the cell and activates the mTOR/S6K pathway (specifically, S6K). A clear connection between PLD with the mTOR/S6K pathway has been established, in that PA binds to mTOR and also binds to S6K independently of mTOR. Lastly, there is evidence in the upstream direction of cell signaling that mTOR and S6K keep PLD2 gene expression function down-regulated in basal conditions. In summary, the involvement of PLD2 in cell signaling continues to expand geometrically. It involves gene transcription, mitogenic and cell migration effects as seen in normal growth, tumor development, and inflammation.

Indexed as

Signal TransductionChemotaxisGene ExpressionHumansInflammationIntracellular Signaling Peptides and ProteinsNeoplasmsPhospholipase DPhosphorylationProtein Serine-Threonine KinasesRibosomal Protein S6 KinasesTOR Serine-Threonine KinasesTyrosineIntracellular Signaling Peptides and ProteinsMTOR protein, humanPhospholipase DProtein Serine-Threonine KinasesRibosomal Protein S6 KinasesTOR Serine-Threonine KinasesTyrosine

Identifiers

PMID20623096
PMCPMC3070604
OpenAlexW2118174648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.